TransCode Therapeutics, Inc.
RNAZ
$7.21
-$0.355-4.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -37.80% | 98.09% | -52.33% | -5.79% | -33.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.58% | 24.28% | -59.22% | -0.18% | -32.71% |
| Operating Income | 3.58% | -24.28% | 59.22% | 0.18% | 32.71% |
| Income Before Tax | -263.27% | -44.73% | 56.20% | -19.56% | 30.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -263.27% | -44.73% | 56.20% | -19.56% | 30.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -263.27% | -44.73% | 56.20% | -19.56% | 30.93% |
| EBIT | 3.58% | -24.28% | 59.22% | 0.18% | 32.71% |
| EBITDA | 3.04% | -24.99% | 59.28% | 0.20% | 32.96% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |